MorphoSys AG (NASDAQ:MOR) Sees Significant Decrease in Short Interest

MorphoSys AG (NASDAQ:MORGet Rating) was the target of a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 169,300 shares, a decline of 11.3% from the August 15th total of 190,800 shares. Based on an average daily trading volume, of 63,600 shares, the short-interest ratio is presently 2.7 days.

MorphoSys Price Performance

Shares of NASDAQ:MOR opened at $5.22 on Monday. The firm has a 50 day moving average of $5.19 and a 200-day moving average of $5.56. The stock has a market capitalization of $714.76 million, a PE ratio of -0.73 and a beta of 1.22. The company has a current ratio of 2.98, a quick ratio of 2.91 and a debt-to-equity ratio of 2.01. MorphoSys has a 12 month low of $4.07 and a 12 month high of $12.64.

MorphoSys (NASDAQ:MORGet Rating) last issued its earnings results on Wednesday, August 3rd. The company reported ($1.83) EPS for the quarter. The firm had revenue of $63.29 million during the quarter. MorphoSys had a negative net margin of 439.59% and a negative return on equity of 345.89%. During the same period in the previous year, the firm earned $0.18 EPS. On average, equities research analysts predict that MorphoSys will post -2.39 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley lifted their target price on shares of MorphoSys from €26.00 ($26.53) to €28.00 ($28.57) and gave the stock an “equal weight” rating in a report on Friday, July 29th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, MorphoSys currently has a consensus rating of “Hold” and an average price target of $32.50.

Hedge Funds Weigh In On MorphoSys

Several hedge funds and other institutional investors have recently made changes to their positions in MOR. Virtu Financial LLC acquired a new position in MorphoSys in the 2nd quarter valued at approximately $53,000. Capricorn Fund Managers Ltd acquired a new position in MorphoSys in the 1st quarter valued at approximately $177,000. OLD Mission Capital LLC acquired a new position in MorphoSys in the 2nd quarter valued at approximately $195,000. Finally, Optiver Holding B.V. acquired a new position in MorphoSys in the 2nd quarter valued at approximately $340,000. 1.82% of the stock is currently owned by institutional investors and hedge funds.

MorphoSys Company Profile

(Get Rating)

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

See Also

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with's FREE daily email newsletter.